S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
NASDAQ:RNA

Avidity Biosciences (RNA) Stock Price, News & Analysis

$22.73
-0.31 (-1.35%)
(As of 04/19/2024 ET)
Today's Range
$22.24
$23.59
50-Day Range
$13.27
$26.87
52-Week Range
$4.82
$27.66
Volume
1.01 million shs
Average Volume
1.18 million shs
Market Capitalization
$1.81 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$36.33

Avidity Biosciences MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
59.8% Upside
$36.33 Price Target
Short Interest
Bearish
12.52% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.99mentions of Avidity Biosciences in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$4.69 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($3.07) to ($3.79) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.02 out of 5 stars

Medical Sector

782nd out of 911 stocks

Pharmaceutical Preparations Industry

351st out of 411 stocks

RNA stock logo

About Avidity Biosciences Stock (NASDAQ:RNA)

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

RNA Stock Price History

RNA Stock News Headlines

Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
RNA Apr 2024 17.500 call
Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
RNA Apr 2024 17.500 put
RNA Apr 2024 22.500 call
A Closer Look at 5 Analyst Recommendations For Avidity Biosciences
Avidity Biosciences Inc
Avidity Biosciences Honors Rare Disease Day®
See More Headlines
Receive RNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Avidity Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/28/2024
Today
4/19/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:RNA
Fax
N/A
Employees
253
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$36.33
High Stock Price Target
$60.00
Low Stock Price Target
$20.00
Potential Upside/Downside
+59.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Net Income
$-212,220,000.00
Net Margins
-2,219.87%
Pretax Margin
-2,219.87%

Debt

Sales & Book Value

Annual Sales
$9.56 million
Book Value
$6.76 per share

Miscellaneous

Free Float
78,125,000
Market Cap
$1.81 billion
Optionable
Optionable
Beta
0.78
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Dr. Troy Edward Wilson J.D. (Age 55)
    Ph.D., Co-Founder & Chairman
    Comp: $67.5k
  • Ms. Sarah Boyce (Age 52)
    President, CEO & Director
    Comp: $1.05M
  • Mr. Michael F. MacLean (Age 58)
    Chief Financial & Chief Business Officer
    Comp: $701.64k
  • Dr. W. Michael Flanagan Ph.D. (Age 62)
    Chief Scientific & Technical Officer
    Comp: $678.74k
  • Ms. Teresa McCarthy (Age 60)
    Chief Human Resources Officer
    Comp: $665.14k
  • Mr. Eric B. Mosbrooker (Age 56)
    Chief Strategy Officer
    Comp: $42.5k
  • Prof. Mark E. Davis
    Scientific Founder, Member of Scientific Advisory Board and Member of Board of Managers
  • Dr. Frank P. McCormick Ph.D. (Age 74)
    Scientific Founder & Member of Scientific Advisory Board
  • Mr. Geoffrey M. Grande C.F.A.
    VP of Investor Relation & Corporate Communication
  • Dr. John W. Wallen III (Age 66)
    VP of Intellectual Property, General Counsel & Secretary

RNA Stock Analysis - Frequently Asked Questions

Should I buy or sell Avidity Biosciences stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avidity Biosciences in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" RNA shares.
View RNA analyst ratings
or view top-rated stocks.

What is Avidity Biosciences' stock price target for 2024?

6 Wall Street analysts have issued 12-month price targets for Avidity Biosciences' stock. Their RNA share price targets range from $20.00 to $60.00. On average, they anticipate the company's share price to reach $36.33 in the next twelve months. This suggests a possible upside of 59.8% from the stock's current price.
View analysts price targets for RNA
or view top-rated stocks among Wall Street analysts.

How have RNA shares performed in 2024?

Avidity Biosciences' stock was trading at $9.05 on January 1st, 2024. Since then, RNA stock has increased by 151.2% and is now trading at $22.73.
View the best growth stocks for 2024 here
.

When is Avidity Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our RNA earnings forecast
.

How were Avidity Biosciences' earnings last quarter?

Avidity Biosciences, Inc. (NASDAQ:RNA) announced its earnings results on Wednesday, February, 28th. The biotechnology company reported ($0.79) earnings per share for the quarter, missing the consensus estimate of ($0.54) by $0.25. The biotechnology company earned $2.19 million during the quarter, compared to analysts' expectations of $32.08 million. Avidity Biosciences had a negative trailing twelve-month return on equity of 39.74% and a negative net margin of 2,219.87%.

What other stocks do shareholders of Avidity Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Avidity Biosciences investors own include GTX (GTXI), Inovio Pharmaceuticals (INO), Novavax (NVAX), Sarepta Therapeutics (SRPT), Avid Bioservices (CDMO), Dynavax Technologies (DVAX), iBio (IBIO), Intel (INTC), Ariad Pharmaceuticals (ARIA) and Corcept Therapeutics (CORT).

When did Avidity Biosciences IPO?

Avidity Biosciences (RNA) raised $150 million in an initial public offering on Friday, June 12th 2020. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. Cowen, SVB Leerink, Credit Suisse and Wells Fargo Securities acted as the underwriters for the IPO.

Who are Avidity Biosciences' major shareholders?

Avidity Biosciences' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Hennion & Walsh Asset Management Inc. (0.09%), Los Angeles Capital Management LLC (0.07%) and Mirador Capital Partners LP (0.06%). Insiders that own company stock include Arthur A Levin, Michael F Maclean, Rtw Investments, Lp, Sarah Boyce and W Michael Flanagan.
View institutional ownership trends
.

How do I buy shares of Avidity Biosciences?

Shares of RNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:RNA) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners